Sol-Gel Technologies (SLGL) AI Stock Analysis

• Market Cap: $243.25M
• Dividend Yield: N/A
• Average Volume (3M): 16.66K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.65
• Revenue Growth: 62.04%
• EPS Growth: 6.10%
• Country: US
• Employees: 34
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.13
• Shares Outstanding: 3,268,991
• 10 Day Avg. Volume: 26,975
• 30 Day Avg. Volume: 16,656
• PEG Ratio: -0.04
• Price to Book (P/B): 5.15
• Price to Sales (P/S): 6.06
• P/FCF Ratio: 426.90
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: 31.24
• Enterprise Value/Gross Profit: -20.35
• Enterprise Value/Ebitda: -12.47
• 1Y Price Target: $110.00
• Price Target Upside: 47.83% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -6.81
• Revenue Forecast (FY): $5.30M

• Rating: 51 Neutral
• Price Target: $84.00 ▲(12.89% Upside)
• Action: Reiterated Date: 03/21/26
• Date: Action: Reiterated 03/21/26

The score is driven primarily by improving financial trajectory (strong 2025 revenue rebound, positive operating/free cash flow, and very low debt) tempered by continued losses and equity erosion. Technicals are mixed/neutral, and valuation is pressured by a negative P/E and no dividend yield.

Positive Factors

Proprietary sol-gel delivery platform and partner model

Owning a proprietary sol-gel drug delivery platform and using partner commercialization reduces single-product commercialization burden and creates licensing/royalty revenue opportunities. This durable technical differentiation supports product-level economics and easier market access through partner networks over multiple years.

Negative Factors

Ongoing net losses and shrinking equity base

Cumulative losses have materially eroded shareholder equity, reducing the balance-sheet cushion for R&D or commercialization setbacks. A thinner equity base limits financial flexibility and increases sensitivity to future dilution or debt financing if operating improvements do not continue.

Sol-Gel Technologies Business Overview & Revenue Model

Company Description

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead ...

Read more

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead ...

How the Company Makes Money

Sol-Gel makes money primarily through (1) net product sales from its own dermatology products where it is responsible for commercialization in its licensed territories, and (2) collaboration and license arrangements in which a partner commercializ...

Read more

Sol-Gel makes money primarily through (1) net product sales from its own dermatology products where it is responsible for commercialization in its licensed territories, and (2) collaboration and license arrangements in which a partner commercializ...

Sol-Gel Technologies Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.56M	19.39M	11.54M	1.55M	3.88M	31.27M
Gross Profit	-10.07M	19.28M	11.30M	-21.99M	-8.80M	10.89M
EBITDA	-16.43M	-7.48M	-10.35M	-28.96M	-15.68M	3.84M
Net Income	-14.91M	-6.13M	-10.58M	-27.24M	-14.92M	3.22M
Balance Sheet
Total Assets	42.01M	29.92M	35.85M	45.29M	46.63M	69.19M
Cash, Cash Equivalents and Short-Term Investments	30.47M	24.00M	23.93M	38.00M	33.63M	43.24M
Total Debt	1.39M	991.00K	1.31M	1.65M	772.00K	1.59M
Total Liabilities	7.10M	7.11M	7.00M	6.64M	4.42M	13.60M
Stockholders Equity	34.90M	22.81M	28.85M	38.64M	42.21M	55.59M
Cash Flow
Free Cash Flow	0.00	275.00K	-13.89M	-17.86M	-9.65M	-7.83M
Operating Cash Flow	0.00	322.00K	-13.89M	-17.73M	-9.48M	-7.69M
Investing Cash Flow	0.00	-8.58M	26.69M	-9.74M	1.70M	19.87M
Financing Cash Flow	0.00	6.00K	0.00	21.81M	15.00K	837.00K

Sol-Gel Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 74.41
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLGL, the sentiment is Positive. The current price of 74.41 is below the 20-day moving average (MA) of 76.00, below the 50-day MA of 77.72, and above the 200-day MA of 43.17, indicating a neutral trend. The MACD of -1.27 indicates Positive momentum. The RSI at 47.97 is Neutral, neither overbought nor oversold. The STOCH value of 38.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLGL.

Sol-Gel Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OVID	56 Neutral	$367.93M	-6.90	-23.98%	―	946.61%	-11.30%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SLGL	51 Neutral	$243.25M	-9.83	-24.29%	―	62.04%	6.10%
STTK	50 Neutral	$484.49M	-7.52	-65.03%	―	-84.46%	33.32%
SRZN	47 Neutral	$342.99M	-0.70	―	―	-63.96%	-28.50%
MGX	47 Neutral	$52.67M	-0.69	-40.87%	―	-43.88%	4.73%
IMDX	45 Neutral	$96.50M	-4.55	684.60%	―	520.87%	36.11%

Sol-Gel Technologies Corporate Events